Osteoporosis Drugs Market Quantitative Analysis From 2019 To 2026 To Enable The Stakeholders To Capitalize On The Prevailing Market Opportunities
Pune, Maharashtra, India, September 11 2020 (Wiredrelease) Allied Analytics –:
Global Osteoporosis drugs market size was valued at $8 billion in 2018, and is expected to reach $10 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026.
Osteoporosis is a medical condition which involves the weakening of the bones. This medical condition is caused due to the overexpression of the parathyroid hormone. Moreover, the weak bones are porous and susceptible to serious fractures. Therefore, osteoporosis has a significant impact on quality of life of patients such as the condition leads to limited mobility. Thus, this medical condition requires treatment which includes the administration of drugs such as bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors and others. Furthermore, these drugs are administered through different routes in the body. For instance, some osteoporosis drugs are administered through the oral route whereas others are administered through the intravenous route.
Download the Sample Report @ https://www.alliedmarketresearch.com/request-sample/1491
The bisphosphonates segment to retain its dominance by 2026-
Based on drug class, the bisphosphonates segment contributed to more than one-third of the global osteoporosis drugs market revenue in 2018 and is expected to dominate from 2019 to 2026. This is owing to increase in investment in R&D of advanced novel bisphosphonates drugs by major players. On the other hand, the rank ligand inhibitors would cite the fastest CAGR of 8.6% by the end of 2026, owing to the fact that these drugs are used to treat bone metastasis by acting as a chemo attractant to bone for tumor cells that expresses its receptor, RANK.
The oral segment to maintain the lion’s share during the estimated period-
Based on route of administration, the oral segment held the major share in 2018, garnering nearly three-fifths of the global osteoporosis drugs market, owing to the large number of osteoporosis medications, which are available as oral drugs in the market. Simultaneously, the injectable segment would manifest the CAGR of 4.4% throughout the forecast period, owing to factors such as rise in need for drugs, which exhibit enhanced bioavailability and act rapidly
North America to lead the trail till 2026-
Based on region, North America accounted for nearly half of the global osteoporosis drugs market share in 2018, and is projected to rule the roost during the study period. Owing to easy availability of osteoporosis drugs and surge in incidence of osteoporosis. At the same time, the LAMEA region would portray the fastest CAGR of 5.5% by 2026. This is attributed to increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. In addition, the constantly evolving life science industry fuels the growth of the market in the developing economies such as India, China, and Malaysia.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1491
Key market players-
Amgen Inc.F. Hoffmann-La Roche AGRadius HealthMerck & Co. Inc.Novartis International AG (Sandoz)Pfizer Inc.Sun Pharmaceutical Industries Ltd.Takeda Pharmaceutical Company LimitedTeva Pharmaceutical Industries Ltd.
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at firstname.lastname@example.org.